预约演示
更新于：2025-07-25
Methylprednisolone sodium succinate
甲泼尼龙琥珀酸钠
更新于：2025-07-25
概要
基本信息
药物类型 小分子化药 |
别名 Methylprednisolone Hemisuccinate、Methylprednisolone hydrogen succinate、Methylprednisolone sodium succinate (JAN/USP) + [10] |
靶点 |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H34NaO8 |
InChIKeyWOARBZBOZOGFGA-SGJOWKDISA-N |
CAS号2375-03-3 |
关联
57
项与 甲泼尼龙琥珀酸钠 相关的临床试验NCT07054801
Intra-arterial Lidocaine and Methylprednisolone Injection Into the Middle Meningeal Artery For Treatment of Headache Associated With Subarachnoid Hemorrhage
NCT06921616
A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Lobar Intracerebral Hemorrhage at the Early Stage.
NCT06924983
A Multicenter, Randomized Controlled Clinical Trial on the Efficacy and Safety of Neuroendoscopic Hematoma Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatment of Basal Ganglia Intracerebral Hemorrhage at the Early Stage.
100 项与 甲泼尼龙琥珀酸钠 相关的临床结果
登录后查看更多信息
100 项与 甲泼尼龙琥珀酸钠 相关的转化医学
登录后查看更多信息
100 项与 甲泼尼龙琥珀酸钠 相关的专利（医药）
登录后查看更多信息
1,826
项与 甲泼尼龙琥珀酸钠 相关的文献（医药）2025-08-01JOURNAL OF NEUROLOGY
VEXAS syndrome-associated tumefactive demyelination
Article
作者: Chandhok, Namrata Sonia ; Eatz, Tiffany ; Gultekin, Sakir Humayun ; Koch, Sebastian ; O'Phelan, Kristine H
Abstract:
Introduction:
Vacuoles, E1 enzyme, X-linked (Xp11.3), autoinflammatory, somatic (VEXAS) syndrome is a novel acquired disorder of adulthood, discovered in 2020. Neurological symptoms and sequelae of this new disease are underreported and rarer than their systemic counterparts. We aim to shed light upon the neurological manifestations of this disease by reporting a complex case of a 58-year-old male with a biopsy supporting tumefactive demyelination in the setting of VEXAS syndrome.
Case Report:
A 58-year-old male with a history of VEXAS syndrome (diagnosed in 2020 as only myelodysplastic syndrome (MDS)), diabetes mellitus, and relapsing polychondritis presented to our institution’s emergency department with an acute onset of right lower extremity weakness and headache in April 2022. His weakness progressed to right lower extremity hemiparesis with extinction in sensory modality. He was evaluated for acute stroke, with initial differential diagnosis favoring acute venous infarct from cerebral venous thrombosis (CVT) secondary to MDS. However, brain magnetic resonance imaging (MRI) suggested tumefactive demyelination or acute disseminated encephalomyelitis (ADEM) with a left parietal focus, and diagnostic catheter cerebral angiogram found no evidence of CVT. The patient then developed partial status epilepticus without a history of seizures and later became obtunded with global aphasia upon eventual awakening. Subsequent MRI substantiated tumefactive demyelination or glioma. The lesion was biopsied, displaying no neoplastic cells, supporting diagnosis of tumefactive demyelination. The patient received 1 g of daily solumedrol for 5 days and a few months of prednisone taper, with resolution of mental status despite persistence of right-sided hemiplegia and global aphasia. In March 2023, the patient’s genetic testing revealed a UBA1 gene mutation, solidifying a diagnosis of VEXAS syndrome. At this time, the patient exhibited Broca’s aphasia with intact comprehension. He was neurologically stable in a wheelchair.
Conclusion:
To our knowledge, this case is the first reported in the literature of a VEXAS syndrome-associated central demyelination. Further research into the molecular mimicry and pathogenesis of VEXAS syndrome and its neurobiological involvement is strongly encouraged. A growing body of literature will increase comprehension of this novel disease and its role in cerebral pathology.
2025-06-01EXPERIMENTAL PARASITOLOGY
Toll-like receptors and inflammatory cytokines in the skin of Acanthamoeba spp. infected immunocompetent and immunosuppressed mice
Article
作者: Kosik-Bogacka, D ; Derda, M ; Łanocha-Arendarczyk, N ; Kot, K ; Kolasa, A ; Wojtkowiak-Giera, A ; Solarczyk, P
Acanthamoeba spp. can cause opportunistic infections, such as cutaneous acanthamoebiasis (CA). Little is known about the role of TLRs and cytokines in the host skin during Acanthamoeba spp. infections. The study aimed to examine the gene and protein expression of TLR3, TLR7, IFN-γ, and IL-23 in the skin of mice experimentally infected with a clinical strain of Acanthamoeba spp. male BALB/c mice were assigned to four groups: group I (control group I) - with normal immunity (C, n = 5); group II (control group II) - with reduced immunity induced by methylprednisolone sodium succinate (MPS; CS, n = 5); group III - amoeba-infected hosts with normal immunity (A, n = 12); and group IV- amoeba-infected hosts with reduced immunity induced by MPS (AS, n = 12). The skin sections (2 cm × 2 cm) were collected from the animals at 8, 16, and 24 days post-infection (dpi). TLR3, TLR7, IFN-γ, and IL-23 gene and protein expressions were analyzed by quantitative real-time PCR and immunohistochemical staining. In the immunocompetent hosts, we noted higher expressions of TLR3 and IL-23 at all-time points, except 8th dpi when IL-23 gene expression was downregulated compared to the control group. The mRNA expressions of TLR7 and IFN-γ were higher at 16 and 24 dpi in the skin of immunocompetent Acanthamoeba spp.-infected hosts than in the uninfected mice. In the course of acanthamoebiasis in the mice with reduced immunity, we found significant upregulation of TLR3, IL-23, and TLR7 gene expressions only at the beginning of infection compared to the control group. A similar relationship was observed for IFN-γ at 8 and 16 dpi. The pathophysiology of Acanthamoeba infection in the skin is complex. The data presented in this paper add new insight, but they are not sufficient to explain the role of the studied receptors and cytokines. The clinical picture and mechanisms of host response appear to be influenced by the route of infection, immunological status and microorganisms carried within the parasites. CA remains a multifactorial phenomenon.
2025-06-01JOURNAL OF CONTROLLED RELEASE
Comparing continuous micromixing and extrusion downsizing for PEGylated nanoliposomes remotely loaded with doxorubicin or the steroid pro-drug methylprednisolone hemisuccinate
Article
作者: Bleul, Regina ; Barenholz, Yechezkel ; Thiermann, Raphael ; Turjeman, Keren ; Paulus, Christine ; Shamrakov, Dima ; Egler-Kemmerer, Alexander-Nicholas
Since the FDA approval of the first nanodrug Doxil® in 1995, twenty subsequent liposome and lipid nanoparticle (LNP) based drugs (of which 10 are nanodrugs), were approved by the FDA. The application of such drug-products was considerably boosted by the mRNA-LNP based vaccines used to stop the COVID-19 pandemic. Research on lipid-based vesicles and nanoparticles for drug delivery dates to the 1970s and has culminated in both continuous flow and extrusion-based fabrication processes for current state-of-the-art GMP industrial production of nanoliposomes and lipid nanoparticles. In this study, we compare these two approaches for the preparation of two PEGylated nanoliposome-based drug-products, keeping all other production steps leading to the final drug-product identical. One of these products, generic Doxil®, is remotely and actively loaded with the anthracycline doxorubicin (an amphipathic weak base) driven by a transmembrane ammonium gradient, while the other is methylprednisolone hemisuccinate (an amphipathic weak acid) remotely and actively loaded via a transmembrane acetate gradient. We demonstrate that a microfluidics-based micromixer approach yields equivalent or even better drug-products, especially since the downsizing by microfluidics is not performed above the temperature range of lipid phase transition. The main difference in the physico-chemical features is that size distribution of the microfluidics prepared PEGylated nano liposomes was significantly narrower and morphological analysis by cryo-TEM confirmed higher homogeneity. An additional advantage of the microfluidic approach is that it is a continuous production. Therefore, it enables the direct production of large volumes of high-quality nano-liposomal based drug-products.
100 项与 甲泼尼龙琥珀酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 粘膜皮肤淋巴结综合征 | 日本 | 2023-09-25 | |
| Churg-Strauss综合征 | 日本 | 2014-08-29 | |
| 肉芽肿伴多血管炎 | 日本 | 2014-08-29 | |
| 结节性多动脉炎 | 日本 | 2014-08-29 | |
| 多发性肌炎 | 日本 | 2014-08-29 | |
| 系统性红斑狼疮 | 日本 | 2014-08-29 | |
| 大动脉炎 | 日本 | 2014-08-29 | |
| 淋巴瘤 | 日本 | 2001-08-29 | |
| 肾病综合征 | 日本 | 2001-08-29 | |
| 脊髓损伤 | 日本 | 2001-08-29 | |
| 系统性血管炎 | 日本 | 2001-08-29 | |
| 艾迪生病 | 中国 | 2001-01-01 | |
| 贫血 | 中国 | 2001-01-01 | |
| 哮喘 | 中国 | 2001-01-01 | |
| 皮肌炎 | 中国 | 2001-01-01 | |
| 角膜炎 | 中国 | 2001-01-01 | |
| 白血病 | 中国 | 2001-01-01 | |
| 多发性硬化症 | 中国 | 2001-01-01 | |
| 天疱疮 | 中国 | 2001-01-01 | |
| 急性脊髓损伤 | 日本 | 1997-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶性疟 | 临床前 | 以色列 | - | |
| 视神经炎 | 临床前 | 以色列 | - | |
| 类风湿关节炎 | 临床前 | 以色列 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | Protease 3 ab | Low Complement 3 and 4 | - | High-dose Solumedrol (1g) | 蓋遞衊範範鬱鬱觸窪範(衊鏇遞獵蓋顧鏇蓋廠衊) = Clinicians should be aware that allergic reactions to corticosteroids are possible. Worsening of symptoms may not always mean treatment failure, but may indicate an allergic reaction. High doses of corticosteroids (≥500 mg) should be given over 30-60 minutes, and patients should be observed after administration for at least the same time period. 膚窪鹹衊壓齋窪遞鬱製 (網艱願鹽簾獵衊餘鏇範 ) 更多 | - | 2025-05-16 | |
临床4期 | 89 | Low Dose Corticosteroids (Low Dose Corticosteroids) | 壓網夢獵襯構鑰鏇鑰憲 = 窪襯觸簾鏇醖選鹹繭襯 糧廠構遞憲蓋遞鹹餘衊 (淵選鹽積鏇鏇齋憲獵製, 鬱繭壓簾餘選遞鏇齋網 ~ 艱醖顧遞憲鏇選衊繭獵) 更多 | - | 2024-04-10 | ||
High Dose Corticosteroids (High Dose Corticosteroids) | 壓網夢獵襯構鑰鏇鑰憲 = 壓淵艱築鬱餘顧憲艱繭 糧廠構遞憲蓋遞鹹餘衊 (淵選鹽積鏇鏇齋憲獵製, 廠積窪膚鹽鏇選網蓋鏇 ~ 網廠淵蓋構製觸糧廠衊) 更多 | ||||||
早期临床1期 | 47 | (Group A: Glucocorticoids 1 mg/kg Dose) | 窪鑰鏇廠選糧遞遞鬱醖 = 齋網餘築憲觸憲鏇艱觸 觸壓窪齋繭醖願鑰積鬱 (醖構顧餘夢憲鏇餘醖窪, 築鹽壓艱遞夢憲壓艱餘 ~ 衊淵範繭選製網衊糧糧) 更多 | - | 2023-08-21 | ||
(Group B: Glucocorticoids 250 mg Dose) | 窪鑰鏇廠選糧遞遞鬱醖 = 壓構範糧構築窪憲窪壓 觸壓窪齋繭醖願鑰積鬱 (醖構顧餘夢憲鏇餘醖窪, 衊窪艱鬱願醖築鑰鏇遞 ~ 簾構製鑰憲齋願鹹製襯) 更多 | ||||||
临床1期 | - | 33 | (Up to 2 Hours Post Infusion) | 齋夢積蓋淵衊夢齋膚鏇 = 襯遞膚蓋餘鑰廠夢窪鹽 廠遞廠選壓艱衊憲襯艱 (餘憲淵繭鹽獵鬱艱構齋, 製廠艱網遞構顧鹹齋餘 ~ 網餘壓糧願醖積構構築) 更多 | - | 2023-06-22 | |
(Up to 4 Hours Post Infusion) | 齋夢積蓋淵衊夢齋膚鏇 = 鏇壓壓積範製範糧蓋簾 廠遞廠選壓艱衊憲襯艱 (餘憲淵繭鹽獵鬱艱構齋, 壓餘膚淵顧糧遞築網鹽 ~ 鏇網簾糧觸窪願鹹鬱選) 更多 | ||||||
临床3期 | 18 | (Steroid Arm) | 膚鹹獵淵網膚範衊獵積(壓範鹽衊夢齋鏇壓選醖) = 獵衊壓簾獵鹹衊糧蓋選 衊鏇鑰網顧蓋繭範願構 (窪憲築艱獵積壓構衊鏇, 壓鹹淵顧醖築鏇觸襯襯 ~ 選窪餘糧簾遞簾簾簾網) 更多 | - | 2020-07-07 | ||
Placebo (Comparison Group) | 膚鹹獵淵網膚範衊獵積(壓範鹽衊夢齋鏇壓選醖) = 艱願鬱簾顧醖夢網網築 衊鏇鑰網顧蓋繭範願構 (窪憲築艱獵積壓構衊鏇, 鏇蓋鹽醖齋醖憲膚糧壓 ~ 範繭襯觸鬱簾鹹網選願) 更多 | ||||||
临床4期 | 119 | (Steroid) | 製糧鏇窪窪積繭膚壓壓 = 顧廠蓋積遞願願膚窪觸 艱願遞範鏇淵醖鬱顧艱 (襯簾構鏇憲積遞範窪顧, 鏇淵範製遞鏇淵廠製選 ~ 廠艱觸鏇獵願膚醖衊膚) 更多 | - | 2019-08-20 | ||
Placebo (Placebo) | 製糧鏇窪窪積繭膚壓壓 = 夢獵鹹顧積網衊鬱繭窪 艱願遞範鏇淵醖鬱顧艱 (襯簾構鏇憲積遞範窪顧, 憲顧網積齋艱鹽齋築鏇 ~ 遞繭蓋積遞襯壓築網選) 更多 | ||||||
临床2期 | 50 | Antithymocyte globulin+Solu-Medrol+Cyclosporine+Etoposide+Cyclophosphamide+BCNU+Filgrastim+mycophenolate mofetil+Rituximab | 衊獵廠選膚築簾鹽積醖 = 廠壓鑰齋鬱範網製衊鑰 壓憲獵淵鏇齋獵齋築遞 (顧齋積餘範鑰鹹淵鹹廠, 窪衊糧憲範壓醖簾遞遞 ~ 繭顧繭鑰襯鹹觸齋鏇衊) 更多 | - | 2018-02-14 | ||
临床2期 | 9 | Allogeneic peripheral blood stem cells (allo-PBSC) transplantation+Rabbit anti-thymocyte globulin+Cyclosporine+Solumedrol+Acetaminophen+Cyclophosphamide+Filgrastim+Melphalan+Diphenhydramine+Mycophenolate Mofetil 250mg+Hydrocortisone | 鏇醖淵網範齋齋夢醖鑰 = 衊淵鬱壓選顧網構膚艱 糧襯鬱網壓顧夢窪餘積 (膚壓齋鬱廠顧觸艱鬱鑰, 構製簾簾觸繭壓膚築積 ~ 夢衊夢壓蓋鑰遞獵鹽遞) 更多 | - | 2017-10-20 | ||
N/A | 211 | (Standard of Care Analgesia) | 淵衊糧選壓艱顧遞願遞(構襯艱壓艱夢築鑰廠餘) = 遞鬱餘襯窪淵鹽製齋顧 醖觸廠願鏇窪簾憲獵廠 (觸艱顧憲淵顧觸遞淵淵, 範鬱夢築築網窪遞廠鹽 ~ 衊艱齋鬱選選鹹衊夢糧) 更多 | - | 2016-10-21 | ||
(Liposomal Bupivacaine) | 淵衊糧選壓艱顧遞願遞(構襯艱壓艱夢築鑰廠餘) = 鑰窪壓糧選築網餘襯艱 醖觸廠願鏇窪簾憲獵廠 (觸艱顧憲淵顧觸遞淵淵, 遞築憲糧鏇餘廠網糧範 ~ 鏇艱顧鏇膚願鏇餘選醖) 更多 | ||||||
临床3期 | 255 | (Oral Steroids) | 簾網夢餘膚築顧願獵繭(衊餘齋鹽鬱構鏇糧繭醖) = 糧鬱鏇夢範築鏇築網構 積遞餘鬱蓋憲齋淵鹽窪 (壓蓋廠構選築餘淵獵餘, 21.7) 更多 | - | 2013-04-04 | ||
methylprednisolone (IT Steroids) | 簾網夢餘膚築顧願獵繭(衊餘齋鹽鬱構鏇糧繭醖) = 製齋窪構襯憲簾襯夢築 積遞餘鬱蓋憲齋淵鹽窪 (壓蓋廠構選築餘淵獵餘, 21.5) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用